Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.89 |
| ▸ | TEC | P42680 | 14/20 | 0.89 |
| ▸ | EGFR | P00533 | 11/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | TXK | P42681 | 1/20 | 0.89 |
| ▸ | BLK | P51451 | 1/20 | 0.89 |
| ▸ | BMX | P51813 | 1/20 | 0.89 |
| ▸ | JAK3 | P52333 | 1/20 | 0.89 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.89 |
| ▸ | MYO3B | Q8WXR4 | 1/20 | 0.89 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22026524 | 1.00 | BTK (0.89) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL29779920 | 1.00 | BTK (0.89) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL20762768 | 0.94 | BTK (1.00) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL29779922 | 0.94 | BTK (1.00) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL22026543 | 0.94 | BTK (1.00) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL22026540 | 0.94 | BTK (1.00) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL22026523 | 0.92 | BTK (0.90) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL29779919 | 0.92 | BTK (0.90) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL29779923 | 0.92 | BTK (0.90) | BTKTECEGFRCYP3A4CYP2C8 | |
| SCHEMBL20762903 | 0.91 | BTK (0.92) | BTKTECEGFRCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2022-09-22 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | BTK 1/4885TEC 4/4885EGFR 551/4885 |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BTK, SYK, LYN | BTK 1/4885TEC 4/4885EGFR 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.